INSIDER · CIK 1861519
Stengone Carmine N.
CEO and President, Director at Contineum Therapeutics, Inc. (CTNM)
↗4 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$81KSold on the market
1Companies
Sep 8, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 202618:08 | Sep 8, 2026 | CTNMContineum Therapeutics, Inc. | CEO and President, Director | S · Sell10b5-1 | $16.46 | −2,500 | 17,217 | -13% | −$41K | ||
| Sep 8, 202618:08 | Sep 8, 2026 | CTNMContineum Therapeutics, Inc. | CEO and President, Director | M · Exercise10b5-1 | $1.01 | +2,500 | 19,717 | +15% | $3K | ||
| Aug 3, 202618:14 | Aug 3, 2026 | CTNMContineum Therapeutics, Inc. | CEO and President, Director | S · Sell10b5-1 | $16.01 | −2,500 | 17,217 | -13% | −$40K | ||
| Aug 3, 202618:14 | Aug 3, 2026 | CTNMContineum Therapeutics, Inc. | CEO and President, Director | M · Exercise10b5-1 | $1.01 | +2,500 | 19,717 | +15% | $3K |